JP6085611B2 - 癌免疫療法 - Google Patents
癌免疫療法 Download PDFInfo
- Publication number
- JP6085611B2 JP6085611B2 JP2014543984A JP2014543984A JP6085611B2 JP 6085611 B2 JP6085611 B2 JP 6085611B2 JP 2014543984 A JP2014543984 A JP 2014543984A JP 2014543984 A JP2014543984 A JP 2014543984A JP 6085611 B2 JP6085611 B2 JP 6085611B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- therapy
- cancer
- immunostimulant
- cell death
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002619 cancer immunotherapy Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 155
- 230000003308 immunostimulating effect Effects 0.000 claims description 63
- 238000002560 therapeutic procedure Methods 0.000 claims description 61
- 229960001438 immunostimulant agent Drugs 0.000 claims description 44
- 239000003022 immunostimulating agent Substances 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 40
- 239000007924 injection Substances 0.000 claims description 34
- 238000002347 injection Methods 0.000 claims description 34
- 230000037449 immunogenic cell death Effects 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 210000004881 tumor cell Anatomy 0.000 claims description 21
- 238000001959 radiotherapy Methods 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 230000010108 arterial embolization Effects 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 241000186359 Mycobacterium Species 0.000 claims description 9
- 238000002428 photodynamic therapy Methods 0.000 claims description 9
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 230000007850 degeneration Effects 0.000 claims description 6
- 230000005865 ionizing radiation Effects 0.000 claims description 6
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 6
- 238000002604 ultrasonography Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000002601 intratumoral effect Effects 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 238000007674 radiofrequency ablation Methods 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 230000008029 eradication Effects 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 239000007928 intraperitoneal injection Substances 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000000315 cryotherapy Methods 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000000015 thermotherapy Methods 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 35
- 230000006378 damage Effects 0.000 description 29
- 239000000427 antigen Substances 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 24
- 108091007433 antigens Proteins 0.000 description 24
- 230000028993 immune response Effects 0.000 description 22
- 230000030833 cell death Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 238000002271 resection Methods 0.000 description 15
- 206010028851 Necrosis Diseases 0.000 description 13
- 230000003211 malignant effect Effects 0.000 description 13
- 230000017074 necrotic cell death Effects 0.000 description 13
- 201000009030 Carcinoma Diseases 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 229960005545 IMM-101 Drugs 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 230000002163 immunogen Effects 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- 239000003504 photosensitizing agent Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 210000002421 cell wall Anatomy 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 238000009169 immunotherapy Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 210000001165 lymph node Anatomy 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 208000037819 metastatic cancer Diseases 0.000 description 7
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000002679 ablation Methods 0.000 description 6
- 230000006020 chronic inflammation Effects 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004900 autophagic degradation Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000011517 stereotactic body radiotherapy Methods 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 241000187918 Mycobacterium obuense Species 0.000 description 4
- 241000187644 Mycobacterium vaccae Species 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 210000001099 axilla Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000008102 immune modulation Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000002350 laparotomy Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- -1 neodymium yttrium aluminum Chemical compound 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000003685 thermal hair damage Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 241000187486 Mycobacterium flavescens Species 0.000 description 2
- 241001532512 Mycobacterium parafortuitum Species 0.000 description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000010317 ablation therapy Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001571 immunoadjuvant effect Effects 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 238000000608 laser ablation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000002720 stereotactic body radiation therapy Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 201000009586 Basophil Adenoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010058553 Diaphragmatic injury Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010019027 Haemothorax Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 206010023129 Jaundice cholestatic Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010072448 Malignant blue naevus Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 206010027193 Meningioma malignant Diseases 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241000983409 Microbacterium terrae Species 0.000 description 1
- 241001314546 Microtis <orchid> Species 0.000 description 1
- 208000013811 Mueller mixed tumour Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000187475 Mycobacterium aichiense Species 0.000 description 1
- 241000187473 Mycobacterium aurum Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 241000187912 Mycobacterium diernhoferi Species 0.000 description 1
- 241001532524 Mycobacterium duvalii Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000187485 Mycobacterium gastri Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187483 Mycobacterium komossense Species 0.000 description 1
- 241000908167 Mycobacterium lepraemurium Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000187491 Mycobacterium nonchromogenicum Species 0.000 description 1
- 241000168058 Mycobacterium peregrinum Species 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 241001509458 Mycobacterium rhodesiae Species 0.000 description 1
- 241000187489 Mycobacterium simiae Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241001532502 Mycobacterium tokaiense Species 0.000 description 1
- 241000187476 Mycobacterium triviale Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 201000005267 Obstructive Jaundice Diseases 0.000 description 1
- 208000007871 Odontogenic Tumors Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000026681 Paratuberculosis Diseases 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 201000009454 Portal vein thrombosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010070627 Tumour rupture Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 208000005310 acidophil adenoma Diseases 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 201000000452 adenoid squamous cell carcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 210000002556 adrenal cortex cell Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 201000005476 astroblastoma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000019493 atypical carcinoid tumor Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011054 breast malignant phyllodes tumor Diseases 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- TVFDJXOCXUVLDH-YPZZEJLDSA-N cesium-131 Chemical compound [131Cs] TVFDJXOCXUVLDH-YPZZEJLDSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000012282 endovascular technique Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 201000005616 epidermal appendage tumor Diseases 0.000 description 1
- 201000010877 epithelioid cell melanoma Diseases 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 208000030316 grade III meningioma Diseases 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- QRWOVIRDHQJFDB-UHFFFAOYSA-N isobutyl cyanoacrylate Chemical compound CC(C)COC(=O)C(=C)C#N QRWOVIRDHQJFDB-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000026267 malignant phyllodes tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 201000009804 nonencapsulated sclerosing carcinoma Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000027825 odontogenic neoplasm Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 208000020351 pituitary gland basophil adenoma Diseases 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000013368 pseudoglandular squamous cell carcinoma Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000002673 radiosurgery Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000018964 sebaceous gland cancer Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000028647 spindle cell neoplasm Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 208000026308 thyroid gland diffuse sclerosing papillary carcinoma Diseases 0.000 description 1
- 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910019901 yttrium aluminum garnet Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Radiation-Therapy Devices (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1120779.2A GB201120779D0 (en) | 2011-12-02 | 2011-12-02 | Cancer therapy |
| GB1120779.2 | 2011-12-02 | ||
| PCT/GB2012/052992 WO2013079980A1 (en) | 2011-12-02 | 2012-12-03 | Immunogenic treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533743A JP2014533743A (ja) | 2014-12-15 |
| JP2014533743A5 JP2014533743A5 (enExample) | 2016-01-28 |
| JP6085611B2 true JP6085611B2 (ja) | 2017-02-22 |
Family
ID=45509083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543984A Active JP6085611B2 (ja) | 2011-12-02 | 2012-12-03 | 癌免疫療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20140356397A1 (enExample) |
| EP (1) | EP2785361B1 (enExample) |
| JP (1) | JP6085611B2 (enExample) |
| KR (1) | KR20140097419A (enExample) |
| CN (1) | CN104023733A (enExample) |
| AU (1) | AU2012343536B2 (enExample) |
| BR (1) | BR112014012880A2 (enExample) |
| CA (1) | CA2857429A1 (enExample) |
| GB (1) | GB201120779D0 (enExample) |
| IL (1) | IL232890A0 (enExample) |
| IN (1) | IN2014MN00955A (enExample) |
| MX (1) | MX2014006511A (enExample) |
| RU (1) | RU2014121335A (enExample) |
| SG (1) | SG11201402396XA (enExample) |
| WO (1) | WO2013079980A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11963716B2 (en) | 2010-07-19 | 2024-04-23 | Emblation Limited | Apparatus and method for the treatment of dermatological diseases or conditions |
| GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| WO2015085162A1 (en) | 2013-12-05 | 2015-06-11 | Rfemb Holdings, Llc | Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb) |
| EP3043863B1 (en) | 2013-09-11 | 2019-12-04 | The Board of Trustees of the Leland Stanford Junior University | Arrays of accelerating structures and rapid imaging for facilitating rapid radiation therapies |
| GB201322725D0 (en) * | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| US11141216B2 (en) | 2015-01-30 | 2021-10-12 | Immunsys, Inc. | Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue |
| RU2733033C2 (ru) * | 2015-06-24 | 2020-09-28 | Иммодьюлон Терапьютикс Лимитед | Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака |
| RU2596505C1 (ru) * | 2015-07-02 | 2016-09-10 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) | Способ лечения онкологических больных цитотоксическими лимфоцитами |
| US10478194B2 (en) | 2015-09-23 | 2019-11-19 | Covidien Lp | Occlusive devices |
| KR20180108655A (ko) | 2016-01-15 | 2018-10-04 | 알에프이엠비 홀딩스, 엘엘씨 | 암의 면역학적 치료 |
| RU2018136347A (ru) * | 2016-04-14 | 2020-05-14 | Фелдрайх Каро Руиз Аб | Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света |
| CA3058380A1 (en) | 2017-03-28 | 2018-10-04 | Emblation Limited | Stenosis treatment |
| EP3654976A1 (en) | 2017-07-21 | 2020-05-27 | Varian Medical Systems, Inc. | Methods of use of ultra-high dose rate radiation and therapeutic agents |
| RU2664597C1 (ru) * | 2017-12-12 | 2018-08-21 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы |
| US20220088231A1 (en) | 2018-12-03 | 2022-03-24 | Fusion Pharmaceuticals Inc. | Radioimmunoconjugates and dna damage and repair inhibitor combination therapy |
| EP3918069A1 (en) * | 2019-01-31 | 2021-12-08 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
| EP4082577A4 (en) * | 2019-12-27 | 2024-01-03 | Zeria Pharmaceutical Co., Ltd. | CANCER TREATMENT METHOD AND DRUG |
| EP4376945A1 (en) * | 2021-07-27 | 2024-06-05 | Immodulon Therapeutics Limited | A mycobacterium for use in cancer therapy |
| CN114367060A (zh) * | 2022-01-13 | 2022-04-19 | 深圳大学 | 激光交变电场联合治疗仪 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5207223A (en) | 1990-10-19 | 1993-05-04 | Accuray, Inc. | Apparatus for and method of performing stereotaxic surgery |
| ATE154759T1 (de) * | 1990-11-08 | 1997-07-15 | Univ London | Mycobacterium als adjuvans für antigene |
| US5458125A (en) | 1994-01-28 | 1995-10-17 | Board Of Directors Of The Leland Standford Jr. University | Treatment planning method and apparatus for radiosurgery and radiation therapy |
| CA2369542C (en) | 1999-04-23 | 2009-10-27 | Qlt Inc. | Immuno-adjuvant pdt treatment of metastatic tumors |
| US20020022032A1 (en) | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
| WO2003049751A1 (en) * | 2001-12-10 | 2003-06-19 | Bakulesh Mafatlal Khamar | The process of manufacturing a pharmaceutical composition useful for management of cancer |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CA2492160A1 (en) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| EP1937303A4 (en) | 2005-10-21 | 2009-11-18 | Med College Georgia Res Inst | INTRODUCTION OF AN INDOLEAMINE-2,3-DIOXYGENASE IN DENDRITIC CELLS BY TLR LIGANDS AND APPLICATIONS THEREOF |
| US20080318252A1 (en) | 2007-04-23 | 2008-12-25 | Scott Kachlany | Rapid assay to test anti-cancer drugs under physiological conditions |
| GB0526033D0 (en) * | 2005-12-21 | 2006-02-01 | Bioeos Ltd | Method |
| EP2010216A4 (en) * | 2006-03-24 | 2010-06-09 | Donald L Morton | MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT |
| WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| US8367075B2 (en) | 2010-07-02 | 2013-02-05 | Indian Institute Of Science | Synergistic combination and method thereof |
| EP2683386B1 (en) * | 2011-03-09 | 2017-07-05 | The Johns Hopkins University | Compounds and methods of use in ablative radiotherapy |
| WO2012177624A2 (en) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| EP2620159A1 (en) | 2012-01-24 | 2013-07-31 | Institut Pasteur | Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria |
| CA2848985A1 (en) | 2012-02-01 | 2013-08-08 | Compugen Ltd. | C10rf32 antibodies, and uses thereof for treatment of cancer |
| US8617520B2 (en) | 2012-02-15 | 2013-12-31 | Immodulon Therapeutics Limited | Cancer therapy |
| GB201308325D0 (en) | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| US10835595B2 (en) | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
| US10975112B2 (en) | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
| RU2733033C2 (ru) | 2015-06-24 | 2020-09-28 | Иммодьюлон Терапьютикс Лимитед | Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака |
| WO2020002905A1 (en) | 2018-06-25 | 2020-01-02 | Immodulon Therapeutics Limited | Cancer therapy |
-
2011
- 2011-12-02 GB GBGB1120779.2A patent/GB201120779D0/en not_active Ceased
-
2012
- 2012-12-03 RU RU2014121335A patent/RU2014121335A/ru unknown
- 2012-12-03 WO PCT/GB2012/052992 patent/WO2013079980A1/en not_active Ceased
- 2012-12-03 JP JP2014543984A patent/JP6085611B2/ja active Active
- 2012-12-03 CA CA2857429A patent/CA2857429A1/en not_active Abandoned
- 2012-12-03 MX MX2014006511A patent/MX2014006511A/es unknown
- 2012-12-03 KR KR1020147016935A patent/KR20140097419A/ko not_active Withdrawn
- 2012-12-03 US US14/361,992 patent/US20140356397A1/en not_active Abandoned
- 2012-12-03 EP EP12799260.0A patent/EP2785361B1/en active Active
- 2012-12-03 IN IN955MUN2014 patent/IN2014MN00955A/en unknown
- 2012-12-03 CN CN201280059421.0A patent/CN104023733A/zh active Pending
- 2012-12-03 BR BR112014012880A patent/BR112014012880A2/pt not_active IP Right Cessation
- 2012-12-03 SG SG11201402396XA patent/SG11201402396XA/en unknown
- 2012-12-03 AU AU2012343536A patent/AU2012343536B2/en active Active
-
2014
- 2014-05-29 IL IL232890A patent/IL232890A0/en unknown
-
2018
- 2018-12-19 US US16/225,028 patent/US11318193B2/en active Active
-
2020
- 2020-06-30 US US16/916,194 patent/US11554166B2/en active Active
-
2023
- 2023-01-13 US US18/154,177 patent/US20230149525A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2857429A1 (en) | 2013-06-06 |
| WO2013079980A1 (en) | 2013-06-06 |
| GB201120779D0 (en) | 2012-01-11 |
| IN2014MN00955A (enExample) | 2015-04-24 |
| AU2012343536A1 (en) | 2014-06-05 |
| IL232890A0 (en) | 2014-07-31 |
| US20190224294A1 (en) | 2019-07-25 |
| AU2012343536B2 (en) | 2017-08-24 |
| NZ624994A (en) | 2016-10-28 |
| SG11201402396XA (en) | 2014-10-30 |
| EP2785361A1 (en) | 2014-10-08 |
| KR20140097419A (ko) | 2014-08-06 |
| CN104023733A (zh) | 2014-09-03 |
| BR112014012880A2 (pt) | 2017-06-13 |
| MX2014006511A (es) | 2014-12-05 |
| US11554166B2 (en) | 2023-01-17 |
| US20200338181A1 (en) | 2020-10-29 |
| US11318193B2 (en) | 2022-05-03 |
| RU2014121335A (ru) | 2016-01-27 |
| EP2785361B1 (en) | 2018-11-28 |
| JP2014533743A (ja) | 2014-12-15 |
| US20140356397A1 (en) | 2014-12-04 |
| US20230149525A1 (en) | 2023-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6085611B2 (ja) | 癌免疫療法 | |
| Yang et al. | Thermal immuno-nanomedicine in cancer | |
| Breton et al. | Microsecond and nanosecond electric pulses in cancer treatments | |
| Moy et al. | Combinatorial immunotherapy and nanoparticle mediated hyperthermia | |
| JP2025185047A (ja) | がんの免疫学的処置 | |
| Ahmed et al. | Improved coagulation with saline solution pretreatment during radiofrequency tumor ablation in a canine model | |
| Keum et al. | Tissue ablation: applications and perspectives | |
| Bai et al. | Advancements and challenges in brain cancer therapeutics | |
| JP2014533743A5 (enExample) | ||
| JP2024506914A (ja) | がんの処置のための多重免疫療法とがんワクチンとを組み合わせた治療用組成物及び方法 | |
| Yu et al. | Microwave ablation induces abscopal effect via enhanced systemic antitumor immunity in colorectal cancer | |
| Tranberg | Local destruction of tumors and systemic immune effects | |
| Yan et al. | Endoscopic Ultrasound‐Guided Intratumoural Therapy for Pancreatic Cancer | |
| Hwang et al. | Endoscopic ultrasound-guided local therapy for pancreatic neoplasms | |
| Peng et al. | Tumor therapeutic modes | |
| Lee et al. | Focused ultrasound as a therapeutic adjunct in pancreatic cancer: from thermal and mechanical effects to immune modulation | |
| US20210154296A1 (en) | Vaccine or immunotherapeutic agent composition containing photothermally treated cell lysates as active ingredients | |
| RU2530523C2 (ru) | Способ противоопухолевой иммунотерапии | |
| NZ624994B2 (en) | Immunogenic treatment of cancer | |
| Zhu et al. | The combination of local treatment and immunotherapy | |
| 李晓松 et al. | Laser immunotherapy: Novel modality to treat cancer through specific antitumor immune response | |
| Testoni et al. | Present and Future of Local Therapies for Unresectable Pancreatic Cancer | |
| Tsen et al. | The emerging role of endoscopists in treating unresectable pancreatic cancer | |
| Song et al. | Synergistic Effects of Cisplatin-epigel and Interstitial KTP Laser Treatment on a Xenografted Squamous Cell Carcinoma | |
| Li et al. | A multimodal neoadjuvant strategy incorporating PDT, RFA, and ICIs results in a notable pathological response and preservation of the sphincter in microsatellite stable low rectal cancer: A highly distinctive case report and literature review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151201 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170105 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170130 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6085611 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |